Back to Market Feed

Historical record - last NADAC effective date: 7/16/2018

Product Information

REVATIO 20 MG TABLET is a brand product labeled by Pfizer Inc., priced at $46.6786 per EA under NDC 00069419068. Its NADAC has been published 294 times since Nov 28, 2013.

FDA first approved this application on Jun 3, 2005. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the sildenafil citrate market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

REVATIO 20 MG TABLET

sildenafil citrate
$46.6786per EA
High Outlier

Strength

20 mg/1

Manufacturer

Pfizer Inc.

NDC

00069419068

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

7/16/2018

Active Ingredients

SILDENAFIL CITRATE

Approval Type

New Drug (NDA)

FDA Application

NDA021845

FDA Approved

6/3/2005

TE Code

AB

On Market Since

6/3/2005

Pharmacological Classes

Phosphodiesterase 5 Inhibitor
Phosphodiesterase 5 Inhibitors

Price Statistics

The NADAC for REVATIO 20 MG TABLET has been published 294 times since Nov 28, 2013, and over the history we have for it it has risen 122.5%. The table below summarizes its recorded NADAC range and movement.

Current price$46.6786 per EA
All-time high$51.0852 (Jul 11, 2018)
All-time low$20.9789 (Nov 28, 2013)
Median price$35.6115
Average price$35.8050
Largest weekly change+9.4% (Jun 8, 2016)
Weeks tracked294
Tracking sinceNov 28, 2013

Price History

1W

N/A

1M

N/A

3M

N/A

6M

N/A

1Y

N/A

3Y

N/A

5Y

N/A

All

+122.5%

Last surveyed Jul 10, 2019 — this NDC no longer appears in the current weekly NADAC file.

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the sildenafil citrate market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

CIALIS 5 MG TABLET
Brand
00002446230•Eli Lilly and Company
$9.2108
per EA
TADLIQ 20 MG/5 ML SUSPENSION
Brand
46287004515•CMP Pharma, Inc.
$13.0703
per ML
CIALIS 10 MG TABLET
Brand
00002446330•Eli Lilly and Company
$53.6874
per EA
CIALIS 20 MG TABLET
Brand
00002446430•Eli Lilly and Company
$53.8373
per EA
ADCIRCA 20 MG TABLET
Brand
66302046760•United Therapeutics Corporation
$67.3444
per EA

Frequently asked questions

What is the NADAC price of REVATIO 20 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for REVATIO 20 MG TABLET, manufactured by Pfizer Inc., is $46.6786 per EA (NDC 00069419068), effective Jul 10, 2019.

How has the price of REVATIO 20 MG TABLET changed over time?

Over the history we have for it, the NADAC for REVATIO 20 MG TABLET has risen 122.5%. It has been tracked across 294 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for REVATIO 20 MG TABLET?

Since Nov 28, 2013, the NADAC for REVATIO 20 MG TABLET has ranged from a low of $20.9789 (Nov 28, 2013) to a high of $51.0852 (Jul 11, 2018), with a median of $35.6115 per EA.

Are there cheaper alternatives to REVATIO 20 MG TABLET?

No other NADAC-published product currently shares the active ingredient and strength of REVATIO 20 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures REVATIO 20 MG TABLET?

REVATIO 20 MG TABLET (NDC 00069419068) is labeled by Pfizer Inc., and CMS classifies it as a brand product.